Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Half-Year Business Results of Domestic Companies: 2 （１）
November 16, 2009
- Share of Original Drugs Not Decreasing Much in Japan Despite Large Fall in Prices: Korosho Survey
November 16, 2009
- Half-Year Business Results of Domestic Companies: 2 （２）
November 16, 2009
- Korosho Considers Revising Medical Fees to Induce Doctors to Prescribe Fewer Antipsychotics
November 16, 2009
- Deeply Cut Prices of New Drugs to Save Failing Healthcare System: Hodanren
November 16, 2009
- REGULATORY NEWS IN BRIEF
November 16, 2009
- Takeda Ties Up with Amylin for Treatment of Obesity
November 16, 2009
- R&D NEWS IN BRIEF
November 16, 2009
- Dr Adachi Confirms ConservativeStance toward Industry Proposal
November 9, 2009
- Generic Amlodipine Comparable to Original Version: NPO Report
November 9, 2009
- Chuikyo Back to Work
November 9, 2009
- Daiichi Sankyo Applies for Injectable Levofloxacin on the Same Day as IP High Court Ruling
November 9, 2009
- Nissui to Launch OTC Version of Epadel in Spring 2010
November 9, 2009
- Cravit's Patent Extension Rejected by IP High Court
November 9, 2009
- OTC Drugs Market Down 1% to ¥774 Bil. in 2008: Yano Research
November 9, 2009
- Generics’Share Lowest in Japan among 15 Advanced Countries
November 9, 2009
- Kenko.com to Sell OTC Drugs On-line From Singapore
November 9, 2009
- Stroke Policy Summit Stresses the Need for Law
November 9, 2009
- R&D NEWS IN BRIEF
November 9, 2009
- Osteoporosis Treatment Effective for Glycemic Control: Prof. Sugimoto
November 9, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…